Edgar Filing: SHREWSBURY STEPHEN B

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â SHREWSBURY STEPHEN B

2. Date of Event Requiring Statement (Month/Day/Year)
10/04/2007

3. Issuer Name and Ticker or Trading Symbol
MAP Pharmaceuticals, Inc. [MAPP]

(Last)

(First)

(Middle)

C/O MAP PHARMACEUTICALS, INC.,Â 2400 BAYSHORE PARKWAY, SUITE 200

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Chief Medical Officer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

MOUNTAIN VIEW,Â CAÂ 94043

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	Â ⁽¹⁾	05/09/2015	Common Stock	33,967	$ 0.64	D	Â
Stock Option (Right to Buy)	Â ⁽²⁾	01/23/2016	Common Stock	25,381	$ 0.74	D	Â
Stock Option (Right to Buy)	Â ⁽³⁾	03/05/2017	Common Stock	25,423	$ 3.36	D	Â
Stock Option (Right to Buy)	Â ⁽⁴⁾	05/01/2017	Common Stock	45,893	$ 6.39	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
SHREWSBURY STEPHEN B C/O MAP PHARMACEUTICALS, INC. 2400 BAYSHORE PARKWAY, SUITE 200 MOUNTAIN VIEW,Â CAÂ 94043	Â	Â	Â Chief Medical Officer	Â

Signatures

/s/ Stephen B. Shrewsbury, M.B., Ch.B.		10/04/2007
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The option is exercisable as it vests: 25% of the total number of option shares granted vests and becomes exercisable on the first anniversary from the vesting commencement date, which is February 22, 2005. Thereafter, the remaining 75% of the total number of option shares vests and becomes exercisable in equal installments cumulatively each month over 36 months, so that the entire number of option shares becomes fully vested and exercisable on the fourth anniversary from the vesting commencement date.
(2)	The option is exercisable as it vests: 25% of the total number of option shares granted vests and becomes exercisable on the first anniversary from the vesting commencement date, which is January 31, 2006. Thereafter, the remaining 75% of the total number of option shares vests and becomes exercisable in equal installments cumulatively each month over 36 months, so that the entire number of option shares becomes fully vested and exercisable on the fourth anniversary from the vesting commencement date.
(3)	The option is exercisable as it vests: 25% of the total number of option shares granted vests and becomes exercisable on the first anniversary from the vesting commencement date, which is March 5, 2007. Thereafter, the remaining 75% of the total number of option shares vests and becomes exercisable in equal installments cumulatively each month over 36 months, so that the entire number of option shares becomes fully vested and exercisable on the fourth anniversary from the vesting commencement date.
(4)	The option is exercisable as it vests: 25% of the total number of option shares granted vests and becomes exercisable on the first anniversary from the vesting commencement date, which is May 2, 2007. Thereafter, the remaining 75% of the total number of option shares vests and becomes exercisable in equal installments cumulatively each month over 36 months, so that the entire number of option shares becomes fully vested and exercisable on the fourth anniversary from the vesting commencement date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.